{"title":"Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.","authors":"Yong Huang, Junjie Cen, Jinhuan Wei, Zhenhua Chen, Yong Fang, Zihao Feng, Jun Lu, Yanping Liang, Junhang Luo, Chengqiang Mo, Wei Chen","doi":"10.3233/CBM-182020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Amplified in breast cancer 1 (AIB1) is a candidate oncogene in human breast cancer, which has been identified to be amplified and overexpressed in several types of other human cancers. Abnormalities of AIB1 and its clinical/prognostic significance, however, in upper tract urothelial carcinoma (UTUC) remain unclear.</p><p><strong>Objective: </strong>To explore what role AIB1 plays in upper tract urothelial carcinoma.</p><p><strong>Methods: </strong>The expression of AIB1 was analyzed using immunohistochemical staining in 133 UTUC patients. Overall, cancer specific and recurrence-free survival rates (OS, CSS, and RFS) were estimated using the Kaplan-Meier method. Multivariable COX regression models containing relevant clinicopathological variables addressed the prediction of postoperative outcome.</p><p><strong>Results: </strong>High AIB1 expression was observed to be associated with increased hazard ratios for 5-year CSS (80.6% vs. 55.8%, p= 0.008) and OS (78.1% vs. 54.8%, p= 0.006). Multivariable analysis revealed that elevated AIB1 expression was an independent prognostic predictor of OS, CSS and RFS. Additionally, pT, pN and hydronephrosis were independently associated with oncologic outcome of UTUC. Three proposed nomograms were proposed to provide an individualized risk estimate of postoperative outcome in patients with UTUC.</p><p><strong>Conclusions: </strong>AIB1 can be used as an independent molecular marker for the prognosis of clinical outcomes of UTUC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"151-160"},"PeriodicalIF":1.9000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182020","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biomarkers : section A of Disease markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-182020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
Background: Amplified in breast cancer 1 (AIB1) is a candidate oncogene in human breast cancer, which has been identified to be amplified and overexpressed in several types of other human cancers. Abnormalities of AIB1 and its clinical/prognostic significance, however, in upper tract urothelial carcinoma (UTUC) remain unclear.
Objective: To explore what role AIB1 plays in upper tract urothelial carcinoma.
Methods: The expression of AIB1 was analyzed using immunohistochemical staining in 133 UTUC patients. Overall, cancer specific and recurrence-free survival rates (OS, CSS, and RFS) were estimated using the Kaplan-Meier method. Multivariable COX regression models containing relevant clinicopathological variables addressed the prediction of postoperative outcome.
Results: High AIB1 expression was observed to be associated with increased hazard ratios for 5-year CSS (80.6% vs. 55.8%, p= 0.008) and OS (78.1% vs. 54.8%, p= 0.006). Multivariable analysis revealed that elevated AIB1 expression was an independent prognostic predictor of OS, CSS and RFS. Additionally, pT, pN and hydronephrosis were independently associated with oncologic outcome of UTUC. Three proposed nomograms were proposed to provide an individualized risk estimate of postoperative outcome in patients with UTUC.
Conclusions: AIB1 can be used as an independent molecular marker for the prognosis of clinical outcomes of UTUC.
背景:AIB1 (Amplified in breast cancer 1, AIB1)是人类乳腺癌的候选癌基因，在其他几种人类癌症中已被证实存在扩增和过表达。然而，AIB1在上尿路上皮癌(UTUC)中的异常及其临床/预后意义尚不清楚。目的:探讨AIB1在上尿路上皮癌中的作用。方法:采用免疫组化染色法分析133例UTUC患者AIB1的表达。总体而言，使用Kaplan-Meier方法估计癌症特异性和无复发生存率(OS, CSS和RFS)。采用包含相关临床病理变量的多变量COX回归模型预测术后预后。结果:AIB1高表达与5年CSS (80.6% vs. 55.8%， p= 0.008)和OS (78.1% vs. 54.8%， p= 0.006)的风险比增加相关。多变量分析显示，AIB1表达升高是OS、CSS和RFS的独立预后预测因子。此外，pT、pN和肾积水与UTUC的肿瘤预后独立相关。提出了三种建议的形态图，以提供UTUC患者术后结局的个体化风险评估。结论:AIB1可作为判断UTUC临床预后的独立分子标志物。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
